Chemical assays of bioactive molecules (in urine, plasma, saliva, etc.). Added value In vitro estimation of ADME/TOX indicators.
Study of interrelationships between tumour neovascularisation, the presence of immunoregulatory cell populations and recurrence or progression in the tumour microenvironment.
Analysis of biomarkers in minimally invasive samples (saliva, blood, cerebrospinal fluid, pleural fluid, etc.), with the aim of improving diagnosis, personalising treatments and monitoring patients more closely (detection of resistance and relapses).
Diagnostic, prognostic and/or predictive biomarkers: in lung cancer, head and neck cancer, colon cancer, breast cancer, melanoma, among others, through different omics approaches (genomics, transcriptomics, metabolomics).
Characterisation and isolation of CSCs from tumour samples. Development of in vitro and in vivo models for the design of new therapeutic strategies to control the CSC population.
